Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

References

• Anon. America’s bone health: the state of osteoporosis and low bone mass in our nation. Washington (DC): National Osteoporosis Foundation; 2002
   Google Scholar
• Anon. Bone health and osteoporosis: a report of the surgeon general. Rockville (MD): US Department of Health and Human Services, Office of the Surgeon General; 2004. Available at http://www.surgeongeneral.gov/library/bonehealth/ [last accessed 26 August 2005]
   Google Scholar
• Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018–26
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis [Fracture Intervention Trial Research Group]. Arthritis Rheum 1999;42:1246–54
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87: 1586–92
   PubMed Web of Science ®Google Scholar
• Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 2005;80:379–88
   PubMed Web of Science ®Google Scholar
• McClung MR, Wasnich RD, Recker R, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 2004;19:11–8
   PubMed Web of Science ®Google Scholar
• Rosen CJ. Postmenopausal osteoporosis. New Engl J Med 2005;353:595–603
   PubMed Web of Science ®Google Scholar
• Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281–9
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis [The Alendronate Phase III Osteoporosis Treatment Study Group]. New Engl J Med 1995;333:1437–43
   PubMed Web of Science ®Google Scholar
• Delmas PD, Recker RR, Chesnut 3rd CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis Int 2004;15: 792–8
   Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [Fracture Intervention Trial Research Group]. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998;280:2077–82
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral Efficacy With Risedronate Therapy (VERT) Study Group]. J Am Med Assoc 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9
   PubMed Web of Science ®Google Scholar
• Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315–22
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005;21:391–401
   PubMed Web of Science ®Google Scholar
• Kassirer JP. Incorporating patients’ preferences into medical decisions. New Engl J Med 1994;330:1895–6
   PubMed Web of Science ®Google Scholar
• Dunbar-Jacob J, Erlen JA, Schlenk EA, et al. Adherence in chronic disease. Annu Rev Nurs Res 2000;18:48–90
   PubMedGoogle Scholar
• Wahl C, Gregoire JP, Teo K, et al. Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes. Healthc Q 2005;8:65–70
   PubMedGoogle Scholar
• Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856–61
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. New Engl J Med 2005;353:487–97
   PubMed Web of Science ®Google Scholar
• Jahng KH, Martin LR, Golin CE, DiMatteo MR. Preferences for medical collaboration: patient–physician congruence and patient outcomes. Patient Educ Couns 2005;57:308–14
   PubMed Web of Science ®Google Scholar
• Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871–86
   PubMed Web of Science ®Google Scholar
• Weiss M, Vered I, Foldes AJ, et al. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 2005;17:143–9
   PubMed Web of Science ®Google Scholar
• Simon JA, Beusterien KM, Hebborn A, Leidy NK. Bisphosphonate dosing preferences in women with postmenopausal osteoporosis: a study. The Female Patient 2005;30:31–6
   Google Scholar
• Gart J. An exact test for comparing matched proportions in crossover designs. Biometrika 1969;56:75–80
   Web of Science ®Google Scholar
• Prescott R. The comparison of success rates in cross-over trials in the presence of an order effect. Appl Stat 1981;30:9–15
   Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Ettinger M, Gallagher R, Amonkar M, et al. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum 2004;50:S513
   Web of Science ®Google Scholar
• Siris ES, Rosen CJ, Harris ST, et al. Adherence rates to bisphosphonate therapy: relationship to bone fractures at 24 months in women with postmenopausal osteoporosis [abstract 397]. Presented at: the sixth international symposium on osteoporosis: current status and future directions, the National Osteoporosis Foundation; April 6–10, 2005, Washington, DC
   Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 2004;15:1003–8
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Better osteoporosis management a priority: impact predicted to soar with aging population. J Am Med Assoc 2005;293:2453–8
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Longer-lasting osteoporosis drugs sought. J Am Med Assoc 2005;293:2458
   Web of Science ®Google Scholar